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In recent years the role of tumor microenvironment in the progression of hematological malignancies has been widely recognized.
Recent studies have focused on how cancer cells communicate within the microenvironment. Among several factors (cytokines,
growth factors, and ECMmolecules), a key role has been attributed to extracellular vesicles (EV), released from different cell types.
EV (microvesicles and exosomes) may affect stroma remodeling, host cell functions, and tumor angiogenesis by inducing gene
expression modulation in target cells, thus promoting cancer progression and metastasis. Microvesicles and exosomes can be
recovered from the blood and other body fluids of cancer patients and contain and deliver genetic and proteomic contents that
reflect the cell of origin, thus constituting a source of new predictive biomarkers involved in cancer development and serving as
possible targets for therapies. Moreover, due to their specific cell-tropism and bioavailability, EV can be considered natural vehicles
suitable for drug delivery. Here we will discuss the recent advances in the field of EV as actors in hematological cancer progression,
pointing out the role of these vesicles in the tumor-host interplay and in their use as biomarkers for hematological malignancies.
1. Introduction
Cell-to-cell communication is necessary in order to maintain
a social and functional order among different cell types
within tissues. A number of intercellular communication
mechanisms mediated, for example, by soluble factors, extra-
cellular matrix components, ion channels, tunneling nan-
otubules, and extracellular vesicles (EV) have been described
[1].
EV are plasma membrane fragments that include, among
several others, microvesicles (MV) and exosomes [2]. MV
enclose a heterogeneous population of vesicles with a size
greater than 100 nm in diameter and are generated by direct
budding off from the plasma membrane; Umezu and col-
leagues; miR-135b; NF-𝜅B [3]. The rate of release of MV is
generally low, except for cancer cells, which show an intense
surface activity and seem to release them constitutively.
Exosomes are vesicles of size ranging from 30 to 100 nm in
diameter and are released into the extracellular compartment
when the multivesicular bodies (MVB) fuse with the plasma
membrane [3].The secretion of exosomes can be spontaneous
or induced, for example, by cell surface receptor activation
[2–4]. The mechanisms of assembly and sorting of exosomes
are not well defined, but several molecules have been shown
to regulate this process, such as RAB11, RAB27, RAB35,
and syndecan-syntenin-ALIX [5–8]. Moreover the ESCRT
(endosomal sorting complex required for transport) member
TSG101 (tumor susceptibility gene 101) and the tetraspanin
CD63, which is enriched in specific plasma membrane
domains involved in microvesicle budding, have both been
described as involved in exosome formation [9]. Recently, the
consideration of the tetraspanin CD63 as a specific exosomal
marker has been reevaluated, since this protein has also been
found in other EV subtypes [10].
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The molecular composition of EV varies depending on
the type and functional state of the producing cell. During
cancer progression, exosomes, released from malignant
cells, are enriched in tumor antigens: for example, exosomes
isolated from ovarian or breast cancer ascites contain tumor
specific antigens HER2/NEU, while MART1 is found in nan-
ovesicles recovered from serum of patients with melanoma
[11].
In addition to proteins and specific lipids, coding and
noncoding RNAs and DNA may be present in EV [1, 12].
Themolecular components found in EV could be transferred
from one cell to another by endocytosis or fusion with the
recipient cell [13, 14]. Of biological interest, the transferred
components are functional in target cells and affect the
phenotype of these cells by modulating gene expression [1,
12, 15, 16]. Thus, EV-mediated intercellular communication
includes the binding of cell-surface receptors on target cells,
followed by induction of cell signaling pathways, transfer
and translation of mRNAs, transfer of microRNAs (miR-
NAs), silencing of mRNA targets, transfer of proteins, and
activation of functions. Moreover, after their release into
the circulation, EV-dependent signaling can occur not only
locally, but also in a paracrine and systemic manner [17, 18].
Even if microvesiculation is a mechanism occurring in all
eukaryotic cells, the amount of EV in the blood is increased
in several pathological conditions, including Alzheimer’s dis-
ease, Crohn’s, immunological disorders, and cancer [19]. EV
have been shown to support tumor invasiveness and metas-
tasis, as well as enhancing angiogenesis. In recent years the
scientific community has focused its attention on the specific
properties of the tumor microenvironment and how these
depend on altered intercellular communication between
malignant cells and nonmalignant cells of the host. A number
of studies have focused on the role played by cancer-cell-
derived EV. For example, the transformation of fibroblasts
and epithelial cells upon uptake of glioblastoma- and breast-
cancer-cell-derived EV was partly dependent on the transfer
of fibronectin and transglutaminase [20]. Cancer cells induce
adaptive mechanisms that rely on phenotypic modulation of
stromal cells in the neighboring tissue and the recruitment of
bone-marrow-derived progenitors from the circulation. This
adaptive remodeling of the tumormicroenvironment, involv-
ing the induction of a large number of effector molecules,
ultimately serves to promote the survival and dissemina-
tion of malignant cells. EV can modulate the stroma, thus
promoting cancer progression and metastasis. Peinado et al.
have recently shown that cancer-derived exosomes modulate
the crosstalk between malignant cells and the bone marrow
(BM) microenvironment. They reported, for the first time,
that metastatic melanoma cells release exosomes that are able
to “educate” BM progenitors, thereby inducing their mobi-
lization, which supports tumor vasculogenesis, invasion, and
metastasis, through the activation of the MET receptor
tyrosine kinase.They found that theMET-activated signaling
proteins are expressed in highlymetastaticmelanomaderived
exosomes and that the transfer of the exosomal receptor
tyrosine kinase MET from tumor-derived exosomes to BM
progenitor cells promotes the metastatic process in vivo.
These results suggest that BM cells retain the educated
phenotype after engraftment into a new host [21]. A recent
study by Melo et al. presents new and significant data on
the role of exosome-shuttled miRNAs in cancer progression.
In particular, the authors show that exosomes derived from
breast cancer cells, and sera from patients, contain DICER
and process pre-miRNAs into mature miRNAs, thus mod-
ulating the recipient cell phenotype. This study points out a
new role for exosomes, which can be considered not only
a shuttle for miRNAs, but also as machinery for miRNA
biogenesis [22].
Hypoxia is a common feature of the microenvironment
of malignant tumors [23, 24] and is associated with tumor
aggression and invasiveness. These effects are mediated, for
example, by hypoxic regulation of cytokine release [25] and
regulation of tumor suppressors and oncogenes [26]. Several
reports have shown a correlation between hypoxia, tumor
progression, and exosome release. For example, King et al.
found a hypoxic enhancement of exosome release by breast
cancer cells [27]. Moreover, exosomes reflect the hypoxic
status of tumor cells by mediating microvascular endothelial
cell (EC) migration and vasculogenesis [28, 29].
Here we will focus on the role of EV in hematological
malignancies and in particular on (i) the role of EV in the
crosstalk between cancer cells and the BM microenviron-
ment; (ii) the role of cancer-cell-secreted EV in angiogenesis;
and (iii) the role of EV as biomarkers of hematologic
malignancies and in mechanisms of drug resistance.
2. EV in the Crosstalk with the
BM Microenvironment
The importance of tumor microenvironment for cancer
progression has, in recent years, been widely recognized.The
microenvironment provides crucial signaling to maintain
tissue architecture, inhibit cell growth, and modulate differ-
entiated phenotypes. On the other hand, incorrect signals
from the microenvironment may lead to destabilization of
tissue homeostasis and to the initiation/promotion of normal
cells to malignancy. Furthermore, the interaction of cancer
cells with their stromal microenvironment overcomes the
physiological barrier function of stromal cells and may also
modulate the invasive andmetastatic phenotype of the cancer
cells, as well as angiogenesis [30]. Several studies in the last
five years have indicated that EV are important components
of the tumor microenvironment and, mediating cell-cell
communication, are currently considered one of the contrib-
utors to tumor progression andmetastasis [31]. Moreover, EV
have been found to contribute not only to primary tumor
growth, but also to the recruitment of microenvironment
resident cells such as ECs or leukocytes (e.g., macrophages,
dendritic cells, and T- and B-cells) [17, 32, 33]. Therefore,
coevolution of the tumor microenvironment with primary
tumor cells is promoted by the crosstalk of different cell types
in a tumor EV-dependent manner [34].
BM is the specific microenvironment of hematological
disease and is composed of a dynamic network of stromal
cells and soluble factors, such as growth factors and cytokines,
thus providing a permissive environment for leukemogenesis
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Figure 1: The bone marrow niche and the major constituents relevant to hematological cancer progression: extracellular vesicles (exosomes
andmicrovesicles) are integral part of tumormicroenvironment, contributing to the development of a suitable niche for hematological cancer
development. Extracellular vesicles released by different cell types allow the bidirectional communication among cancer cells and normal host
cells.
and cancer progression (Figure 1). In acute myeloid leukemia
(AML), exosomes released from leukemia cells alter the
proliferative and migratory responses of cocultured stromal
and hematopoietic progenitor cells, helping to explain how
the microenvironmental niche becomes reprogrammed dur-
ing invasion of the BM by AML cells. Specifically, Huan
et al. showed the presence of transcripts with prognostic
relevance in AML, human CXCR4 and IGF-IR (insulin-like
growth factor-I receptor)mRNA, inmurine BMstromal cells,
thus demonstrating that AML exosomes transfer leukemia-
derived mRNAs to BM stromal cells. Moreover, they found
that exosomal transfer of IGF-IR can modulate proliferative
signaling in bystander cells and can promote expression
of VEGF, with the final establishment of conditions that
contribute to leukemic spread [35].We recently provided data
showing that chronic-myeloid-leukemia- (CML-) derived
exosomes are able to stimulate bone marrow stromal cells
(BMSC) to release IL8, which acts as an in vitro and in
vivo prosurvival factor for CML cells. The inhibition of IL8
receptors, using SB225002, was able to abrogate the IL8-
driven CML cell survival in vitro as well as the growth
of CML xenograft in vivo, thus indicating a key role of
CXCLl8/CXCR1-2 signaling in the growth of CML cells [36].
It is conceivable that IL8 secreted by the BM and ECs
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under the stimulation of CML exosomes may modulate both
myeloid malignant cells and the BM cellular compartment,
thus generating a paracrine loop between hematopoietic
malignant cells and resident cells. Our unpublished data
further shows that the CML-exosome-mediated release of
IL8 by BMSC relies on the activation of the EGF receptor
pathway. On the other hand, IL8 is able to activate, in CML
cells, an AXLmediated pathway that could be responsible for
leukemia cell survival (unpublished data). Ghosh et al. found
that EV isolated from plasma of B-cell chronic lymphocytic
leukemia (CLL) patients can interact and modulate BMSC,
thus providing a “homing and nurturing” environment for
CLL B cells. In particular, they demonstrated that CLL-
EV can maintain the AKT/mTOR/p70S6K/HIF-1𝛼 axis in a
sustained state of activation and can potentially modulate
the AKT/GSK3𝛽 or AKT/𝛽-catenin signaling pathways. This
leads to the establishment of a tumor microenvironment that
favors disease progression [37].
Cell-to-cell communication can also occur between
leukemia cells and normal neutrophils, thus providing a
mechanism for tumor development. Cai’s group found that
Bcr/Abl hybrid gene, involved in the pathogenesis of CML,
could be transferred throughK562 EV to normal neutrophils.
Incubation of neutrophils withK562-EV for 24 hours resulted
in the expression of the Bcr/Abl hybrid gene in 20% of the
cells [38]. Moreover, the same group showed that injection
via tail vein of K562 EV into Sprague-Dawley (SD) rats or
NOD/SCID mice caused several symptoms of CML in the
animals, such as weakness, loss of weight, splenomegaly,
and neutrophilia, but reduced neutrophil phagocytic activ-
ity. Disease development was accompanied with de novo
transcription, as well as protein synthesis of BCR/ABL in
vivo, demonstrating that the transfer of the Bcr/Abl gene
from CML-derived EV to neutrophils may promote in vivo
transformation of normal cells [39]. During tumor develop-
ment, neoplastic cells actively recruit cells of the immune
system, which may provide an immunosuppressive and
growth-promoting compartment [40]. Recently, numerous
studies have shown that microenvironmental stressors such
as low pH, heat, and oxidative stress modulate the molecular
composition of EV [41]. For example, leukemia/lymphoma
T- and B-cells under a thermal and oxidative stress release
exosomes enriched in Natural Killer Group 2, member D
(NKG2D) ligands, which abrogate NKG2D-mediated NK-
cell cytotoxicity and, thus, may contribute to the immune
evasion of leukemia/lymphoma cells [42]. Stromal cells, sim-
ilarly to cancer cells, can respond to stress-related conditions
within the tumor microenvironment by secretion of EV. For
example, mesenchymal stem cells stimulated by hypoxia were
shown to releaseMVwith angiogenic potential [43]. Roccaro
et al. reported that multiple-myeloma-BM-mesenchymal-
stromal-cell- (MM-BMSC-) derived exosomes played a role
in multiple myeloma (MM) disease progression in vivo.
In particular, they showed that BMSC transfer exosomes
containing miR-15a into MM cells, inducing their prolifera-
tion and survival. Importantly, whileMM-BM-MSC–derived
exosomes promoted MM tumor growth, normal BM-MSC
exosomes inhibited the growth of MM cells. These observa-
tions suggest the establishment of paracrine growth circuits
between BM-MSC and clonal plasma cells and that the BM
niche, educated by tumor exosomes, provides an optimal
substrate for MM cell localization and growth [44]. The
data reported here underscore the importance of the tumor
microenvironment for cancer progression. In particular,
in the context of hematological malignancies, we found
examples of the role of EV released by cells of hematological
malignancies in the crosstalk with BM resident cells.
3. EV in Angiogenesis
The tumor vasculature is an important component of the
tumor microenvironment. Tumors are endowed with angi-
ogenic-inducing capability, and their growth, invasion, and
metastasis are angiogenesis-dependent [45]. Over the last few
years, many studies have focused their attention on the role
of these vesicles in modulating angiogenic processes [46]. EV
possess the ability to modulate tumor angiogenesis, depend-
ing on their origin and composition, by inducing changes in
target cells or by delivering angiogenic proteins or miRNAs
that can stimulate EC function. Here we will focus on the
role of EV in hematological disorders. Increased angiogen-
esis has been observed in hematologic disorders, including
acute and CML, acute and chronic lymphocytic leukemia,
MM, and lymphomas [47–50]. BM microvessel density, a
measure of tumor angiogenesis, is greater in patients with
advancedmyelodysplastic syndromes compared with normal
individuals, thus confirming a central role of the process in
these disorders [51]. In recent years, we and other groups
have focused research on the role of exosomes derived from
chronic myelogenous leukemia cells in promoting angiogen-
esis. Taverna et al. showed that exosomes released from CML
cells directly affect ECs by modulating the process of neovas-
cularization, both in vitro and in vivo, by inducing in ECs
the release of proangiogenic cytokines, such as Interleukin-
8 [52]. We have also shown that imatinib-resistant CML cells
release exosomeswith proangiogenic abilities, suggesting that
themodulation of their function could be considered for new
approaches in CML treatment [53]. Mineo et al. reported
that exosomes released by K562 CML cells are internalized
by ECs during tubular differentiation on Matrigel and are
transferred to neighboring cells through the formation of
nanotubular structures connecting the cells. Furthermore,
the authors showed that these exosomes stimulate tube
formation in ECs through SRC activation [54]. It is now
widely known that EV contain miRNAs and that they are
delivered in the tumor microenvironment [12, 55]. To date,
many angiogenic miRNAs have been identified, and several
have been shown to play important roles in exosome-
mediated modulation of angiogenesis. Taverna et al. recently
found that miR-126, a miRNA involved in angiogenesis,
was expressed 6-fold more in LAMA84 exosomes compared
with the parental cells. The exosomal transfer of miR-
126 to ECs directly targeted the 3󸀠 UTR of Cxcl12 and
Vcam1 mRNA, thus modulating adhesive and migratory
abilities of CML cells [56]. Other groups have found that
exosomes released from K562 cells contain specific miRNAs,
which enhanced EC migration and tube formation [57, 58].
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Umezu et al. reported that miR-92 derived from K562 cells
was transferred to ECs through exosomes, thus promoting
endothelial migration and tube formation [57]. It is well
established that hypoxia plays a role in boosting tumor angio-
genesis.Many studies have shown that the exposure of human
cancer cells to hypoxia augments microvesicle shedding in
order to modify their microenvironment to facilitate tumor
angiogenesis and metastasis [59]. Moreover, microarray and
proteomic studies have highlighted the increase of many
proangiogenic factors in EV released after hypoxic stimuli
[58, 60]. Tadokoro and colleagues reported that the hypoxic
human leukemia cell line K562 secretes exosomal miRNAs,
which enhances tube formation in human umbilical vein
ECs due to inhibition of the receptor tyrosine kinase ligand
EPHRIN-A3. In particular, they found that hypoxic exosomes
contained higher levels of miR-210, indicating a difference
between normoxic and hypoxic exosomes [58]. In AML, the
release of EV has been described in vitro as well as in the sera
of patients affected with the disease. Kurre’s group has shown
that AML exosome trafficking alters the angiogenic responses
of cocultured stromal and hematopoietic progenitor cell
lines, thus influencing the invasion of the BM [35]. BM
angiogenesis also plays an important role in the pathogenesis
and progression of MM. The tumor-host interplay, driven
by EV, in MM has been recently established. Liu et al.
reported, for the first time, that myeloma RPMI 8226 cells
can secrete MV harboring oncogenic CD138, a specific type
of angiogenic regulator, and the incorporation of the MM-
MVs into ECs leads to the reprogramming of the ECs. Specif-
ically, exosome stimulation promotes EC proliferation and
the invasion and the secretion of the proangiogenic factors
IL6 and VEGF [61]. Recently, Umezu and colleagues have
established an in vitro system of hypoxic-resistant multiple
myeloma cells (HR-MM),which serves as amodel of therapy-
resistant MM cells. The authors showed that the amount
of exosomes from HR-MM cells was significantly greater
than that of parental cells and that specific miRNAs were
present. They found that hypoxia-driven accelerated tube
formation is attributable to exosomalmiR-135b, an oncogenic
miRNA shed from HR-MM cells. Specifically, they found
that miR-135b directly targets and inhibits FIH-1, which is
an asparaginyl hydroxylase enzyme binding to HIF-1𝛼, thus
inhibiting its transactivation. In this way, exosomal miR-135b
accelerated HIF-1 transcriptional activity via inhibition of
FIH-1 [60]. Together, these data highlight the crucial role of
EV in tumor-host communication, thus contributing to the
progression and dissemination of cancer cells through the
modulation of angiogenic processes.
4. EV as Biomarkers of Hematological
Malignancies and Their Role in Mechanisms
of Drug Resistance
The identification of new biomarkers differentially expressed
in cell populations, as well as in patients, is of primary
importance in the detection, diagnosis, and prognosis of
cancer. Biologically active exosomes isolated from human
plasma can be proposed as new and intriguing biological
markers [62]. Because EV (both MV and exosomes) contain
genetic and proteomic contents that reflect the cell of origin,
it is possible to detect tumor-specific material in EV secreted
by cancer cells.
It has been clearly shown that the release of bothMV and
exosomes is dramatically enhanced during cancer progres-
sion.Moreover, EV can be recovered frombody fluids and the
circulation of cancer patients, thereby constituting a source of
new predictive biomarkers involved in cancer development
and potentially serving as an information-rich prognostic
[63–65].Working as shuttles, EV can protect their cargo from
nucleases and proteases, increasing the biomarker half-life
and potentially facilitating sample integrity and downstream
analyses [66]. EV-associated cancer biomarkers have been
extensively described in a great number of solid cancers,
such as prostate cancer, melanoma, and lung cancer [21, 67–
70]. Furthermore, in patients affected with melanoma and
other solid tumors, total protein levels of exosome fractions
isolated from plasma were reported to reflect disease stage,
tumor burden, response to therapy, and survival [21, 71, 72].
However, EV derived from hematological cancer cells have
been less studied than those derived from solid tumor cells.
An interesting study showed that in AML, exosomal protein
levels may reflect the extent of disease and correlate with
its relapse after therapy. Large differences were noted in
exosomal protein levels among patients uponAMLdiagnosis,
and the authors suggested that low exosomal protein levels
may be predictive of long-term disease survival. In addition,
change in exosomal protein levels may reflect response to
chemotherapy, and the exosomal profile analysis may detect
residual leukemia cells in patients considered in complete
remission. More specifically, TGF-𝛽1 levels were analyzed
and compared among patient cohorts, and the changes in
exosome-associated TGF-𝛽1 levels were evaluated in rela-
tion to the therapy given to AML patients. The authors
found that the TGF-𝛽1 levels upon AML diagnosis were
higher than those in exosomes of normal controls. Following
chemotherapy treatment, TGF-𝛽1 levels were significantly
reduced, while patients in long-term complete remission
had low exosomal TGF-𝛽1 levels. The authors suggested that
change in exosomal TGF-𝛽1 levels may reflect responses
to chemotherapy. According to the authors, these data
reinforced the relevant role of AML-derived exosomes as
potential diagnostic or prognostic biomarkers [71].
EV shuttle diverse RNA species, including mRNAs and
miRNAs, to recipient cells, and affect the metabolism of
target cells. In addition, several data have shown that miRNA
content from their originating cancer cells is similar to that
found in circulating exosomes [73]. Exosomes derived from
both AML and CML cells were enriched for several coding
and noncoding RNAs relevant to both cancer prognosis
and treatment, as well as to the leukemic niche function.
Still, CML-derived exosomes are characterized by selectively
expressed miRNAs and plausibly suggested as possible future
biomarkers [35]. A recent study identifiedmiR-155 as a useful
biomarker in individuals with monoclonal B-cell lymphocy-
tosis and in patients with B chronic lymphocytic leukemia.
The authors found higher miR-155 levels expression in
patients who failed to respond to chemotherapy compared
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with those who experienced complete response. Further-
more, the authors identified miR-155 in circulating MV from
both individuals with monoclonal B-cell lymphocytosis and
patients with chronic lymphocytic leukemia [74].
Because the residual disease in patients considered in
complete remission is difficult to investigate with conven-
tional methods, the need to elaborate alternative tests for
detecting residual disease will become more pressing in
future studies. At present,miRNA-based clinical trials involv-
ing exosomes have not been initiated because an improved
characterization of these carriers and their cargos in normal
and disease models is still needed [41].
Thedevelopment of chemotherapeutic resistance is one of
the major factors that contribute to cancer mortality.Though
a combination of molecular mechanisms is responsible for
drug resistance, the role played by EV in modulating the
acquisition of the chemoresistant phenotype is increasingly
emerging [41, 75–79]. The effect of BMSC-derived exosomes
on the survival and drug resistance of MM cells, using
both a murine model and human MM samples, has been
investigated in MM. The authors found drug resistance
to bortezomib in MM cells treated with BMSC-derived
exosomes, as well as the activation of several pathways
related to drug resistance and cell survival, such as NOTCH1,
STAT3, NF-𝜅B, and AKT [80]. In another study, Aung et
al. found, both in vitro and in vivo, a strong exosome
production and release from aggressive B-cell lymphoma
cells. Such lymphoma-derived exosomes carried the protein
CD20, exposed in themembrane, able to intercept rituximab,
and thus allowing lymphoma cells to escape from humoral
immunotherapy [81]. Because exosomal CD20 is a decoy
target for rituximab, the authors suggested that the drug
sequestered by circulating exosomes may reduce the efficacy
of pharmacological treatment [81].
Cancer cells exposed to chemotherapeutic agents are able
to expel drugs in extracellular compartments using special-
ized transporters of the multidrug resistant ATP binding-
cassette transporter (ABC transporter). Recent studies have
indicated that leukemia cells express ABCA3 transporters
and that their expression is correlated with decreased sus-
ceptibility to cytostatic therapy. ABCA3 is localized inside
the limiting membranes of multivesicular bodies in which
drugs are efficiently sequestered [81–84]. It is now clear
that exosomes from different malignant cells carry ABC
transporters, and some studies have shown that drugs may
also be expelled from the cells through exosomalmechanisms
[41, 81, 85, 86]. Finally, immunotherapy studies in aggressive
B-cell lymphoma demonstrated for the first time that exoso-
mal evasion of humoral immunotherapy was modulated by
ABCA3 [81].
Collectively, these studies provide evidence that EV in
hematological malignancies play an important role in cancer
drug resistance, thus influencing response to therapy andpro-
moting cancer progression. Advances in the understanding of
cancer-derived EV biology, as well as in the development of
new sophisticated technologies aimed at isolating and char-
acterizing EV, will be clinically relevant to the identification
of new prognostic or predictive biomarkers in hematological
malignancies.
5. Concluding Remarks
EV have been widely recognized as important actors in cell-
cell communication by delivering messages among different
cell types. This finding has opened new questions in the
field of cancer research, allowing a new interpretation of the
tumor microenvironment and of targeted therapies. Here we
focused on the role of EV in hematological malignancies,
reporting evidence of the importance of these vesicles in
modulating cancer properties. Furthermore, EV compo-
nents can now be considered biomarkers in hematological
neoplasia, thus providing important findings for the early
diagnosis of these malignancies and the design of alternative
approaches to cancer therapy.
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